Aisling Capital

Developing late-stage neuroscience compounds targeting migraine and psychiatric disorders.

Novel treatments for people living with narcolepsy and other central nervous system disorders.

CoolSculpting®: more science, less fat.

Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy

AISLING CAPITAL IS A LEADING INVESTMENT FIRM THAT INVESTS IN COMPANIES DEVELOPING AND COMMERCIALIZING IMPORTANT AND INNOVATIVE HEALTHCARE PRODUCTS, SERVICES AND TECHNOLOGIES

A combined 150+ years of experience in the healthcare industry

$1 8 billion in assets, with a track record of investing and returning capital since 2000

Spruce Biosciences And Kaken Pharmaceutical Announce Strategic Partnership And Exclusive Licensing Agreement To Develop And Commercialize Tildacerfont For CAH In Japan

Verona Pharma Announces Ensifentrine Meets Primary And Key Secondary Endpoints In Phase 3 ENHANCE-1 Trial For COPD

Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted For Revumenib For The Treatment Of Adult And Pediatric Patients With Relapsed Or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia